H., Bergmann, M
From a regulatory standpoint, Epithalon is not FDA-approved and lacks comprehensive human safety data within Western regulatory frameworks
Usually given by a healthcare professional
It acts as a dual agonist at amylin receptors (AMY1R, AMY2R, AMY3R, formed by calcitonin receptor heterodimerized with RAMP1-3) and calcitonin receptors, with structural modifications (e.g., N-terminal fatty acid acylation, proline substitutions) preventing fibril formation, enhancing stability, and enabling once-weekly dosing via albumin binding for prolonged circulation
Anyone with evidence of scalp inflammation (itching, redness, seborrheic dermatitis) where the anti-inflammatory mechanism is directly relevant
Costochondritis, an inflammation of the cartilage connecting the ribs to the breastbone, is a common cause of NCCP